Diffuse large B-cell lymphoma trials in Spain

In Spain 24 Also abroad 346

24 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Where
Seville
Age
18 years and over
People
180 worldwide
Run by
ModeX Therapeutics, An OPKO Health Company
See details and how to joinNCT07249905
Phase 3Taking people
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Where
A Coruña, Badalona, Barcelona, Granada, Madrid, Oviedo, Palma, Pamplona, Pozuelo de Alarcón, Sabadell, Santander, Santiago de Compostela, Seville, Terrassa, Toledo, Valencia
Age
18 years and over
People
904 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00
Phase 1Taking people
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Where
L'Hospitalet de Llobregat, Madrid
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00
Phase 1Taking people
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Where
Badalona, Madrid, Salamanca
Age
18 years and over
People
140 worldwide
Run by
Iksuda Therapeutics Ltd.
See details and how to joinNCT05365659
No phaseTaking people
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Where
Madrid
Age
10 years and over
People
210 worldwide
Run by
Leuko Labs, Inc.
See details and how to joinNCT06323447
Phase 1Taking people
A Study of ARC-02 in B-cell NHL
Where
Barcelona, Cáceres, Madrid, Sevilla
Age
18 years and over
People
140 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Barcelona, Esplugues De Llobregat, Madrid, Valencia
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 2Not yet taking people in Spain
HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before
Where
DO NOT EDIT
Age
65 years and over
People
276 worldwide
Run by
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2025-524230-25-00 · EU 2025-524230-25-00
Phase 3Taking people
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Where
Alicante, Barakaldo, Barcelona, Gijón, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Sevilla, Zaragoza
Age
18 years and over
People
1,046 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00
Phase 1Taking people
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Where
Barcelona, Castello De La Plana, L'Hospitalet de Llobregat, Madrid, Málaga, Pozuelo de Alarcón, Valencia
Age
18 years and over
People
453 worldwide
Run by
Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Barcelona, Madrid, Majadahonda, Valencia
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 2Taking people
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
Where
Badalona, Barcelona, Bilbao, Burgos, Cáceres, El Palmar, Madrid, Marbella, Oviedo, Palma de Mallorca, Salamanca, San Cristóbal de La Laguna, Seville, Valencia, Zaragoza
Age
18 years and over
People
80
Run by
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
See details and how to joinNCT07126236 · EU 2024-514440-86-00
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Barcelona, Girona, Madrid, Majadahonda, Palma, Pamplona, Pozuelo de Alarcón, Sabadell, Salamanca, Santiago de Compostela, Sevilla, Valencia
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
Phase 1Taking people
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Where
Madrid, Pamplona
Age
18 years and over
People
85 worldwide
Run by
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00
Phase 1Taking people
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Where
Barcelona, Gijón, Madrid
Age
18 years and over
People
572 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00
Phase 2Taking people
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Salamanca, Sevilla
Age
18 years to 70 years
People
213 worldwide
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00
No phaseTaking people
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Where
A Coruña, Badalona, Burgos, Córdoba, Manises, Marbella, Murcia, Pamplona, Sabadell, Santa Cruz de Tenerife, Seville, Valladolid
Age
18 years and over
People
700 worldwide
Run by
AbbVie
See details and how to joinNCT06830759
Phase 1Taking people
Study of SGR-1505 in Mature B-Cell Neoplasms
Where
L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca
Age
18 years and over
People
98 worldwide
Run by
Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00
Phase 2Taking people
Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma
Where
A Coruña, Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Murcia, Palma de Mallorca, Pamplona, Salamanca, San Sebastián, Santander, Seville, Valencia
Age
18 years and over
People
45
Run by
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
See details and how to joinNCT07254754
Phase 1/2Taking people
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Where
Barcelona, Madrid, Murcia, Salamanca, Santander, Seville, Valencia, Zaragoza
Age
18 years and over
People
37
Run by
IDP Discovery Pharma S.L.
See details and how to joinNCT05908409
Phase 2Taking people
LATE-R trial. A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma
Where
A Coruña, Barcelona, Donostia, Las Palmas De Gran Canaria, L'Hospitalet de Llobregat, Madrid, Murcia, Palma, Pamplona, Salamanca, Santander, Sevilla, Valencia
Age
18 years and over
People
45
Run by
Fundacion Geltamo
See details and how to join2024-512835-53-00 · EU 2024-512835-53-00
No phaseTaking people
Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment
Where
Salamanca
Age
18 years and over
People
40
Run by
Instituto de Investigación Biomédica de Salamanca
See details and how to joinNCT06439173
Phase 2Taking people
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Barcelona, Burgos, Seville
Age
18 years and over
People
102 worldwide
Run by
ImmunoVaccine Technologies, Inc. (IMV Inc.)
See details and how to joinNCT04920617
Phase 1/2Taking people
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Salamanca, Valencia
Age
18 years to 64 years
People
37 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT03356054 · EU 2023-510556-22-00